ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.59 and traded as high as $6.72. ImmuCell shares last traded at $6.62, with a volume of 2,570 shares traded.
ImmuCell Price Performance
The company has a current ratio of 4.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.30. The business has a fifty day simple moving average of $6.38 and a 200 day simple moving average of $5.61. The stock has a market capitalization of $61.74 million, a P/E ratio of -97.56 and a beta of 0.32.
ImmuCell (NASDAQ:ICCC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported $0.16 earnings per share for the quarter. The business had revenue of $8.07 million during the quarter. ImmuCell had a negative return on equity of 1.02% and a negative net margin of 1.00%.
Institutional Investors Weigh In On ImmuCell
Large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC bought a new stake in ImmuCell during the 4th quarter valued at approximately $149,000. Northern Trust Corp boosted its position in ImmuCell by 51.0% during the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after acquiring an additional 14,982 shares in the last quarter. Geode Capital Management LLC boosted its position in ImmuCell by 13.9% during the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock valued at $332,000 after acquiring an additional 7,878 shares in the last quarter. Finally, Dauntless Investment Group LLC bought a new stake in ImmuCell during the 4th quarter valued at approximately $676,000. Hedge funds and other institutional investors own 13.47% of the company's stock.
About ImmuCell
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
See Also
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access